Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K Current report
- 2.1 Agreement and Plan of Merger
- 23.1 Consents of Experts and Counsel
- 99.1 Press Release
- 99.2 Corporate Presentation
- 99.3 Description of Business and Risk Factor Update
- 99.4 the Audited Financial Statements of First Wave Bio
- 99.5 the Unaudited Interim Financial Statements of First Wave Bio
- 99.6 the Unaudited Pro Forma Condensed Consolidated Financial Statements
- Download Excel data file
- View Excel data file
ENTO similar filings
- 28 Sep 21 Other Events
- 21 Sep 21 Material Modifications to Rights of Security Holders
- 14 Sep 21 AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
- 13 Sep 21 Entry into a Material Definitive Agreement
- 10 Sep 21 AzurRx BioPharma Announces Reverse Stock-Split
- 18 Aug 21 AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination
- 16 Aug 21 AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors
Filing view
External links
EXHIBIT 23.1
CONSENT OF INDEPENDENT PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-1 (File Nos. 333-235768 and 333-252087), Form S-8 (File No. 333-220781) and Form S-3 (File Nos. 333-226065, 333-231035, 333-231954, 333-240129, 333-252623 and 333-256476) of AzurRx BioPharma, Inc. of our report dated August 30, 2021 with respect to the balance sheets of First Wave Bio, Inc. as of December 31, 2020 and 2019 and the related statements of operations, stockholders’ equity (deficit), and cash flows, for the years then ended, which report appears in the Form 8-K of AzurRx BioPharma, Inc. dated September 13, 2021.
/s/ Plante & Moran, PLLC
Southfield, Michigan
Consent Date